Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu and currently employs 5,568 full-time employees. The company went IPO on 2015-12-30. The firm operates through four segments. The Life-Science Services and Products segment provides comprehensive reagent services and products, instruments and custom-tailored solutions for gene therapy, cell therapy, antibody therapeutics, vaccines and diagnostics. The Biologics Development Services segment provides comprehensive services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production by non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment is engaged in the discovery and development of novel cell therapies for oncology and other indications.
Follow-Up Questions
What is the price performance of GNNSF stock?
The current price of GNNSF is $2.25, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Genscript Biotech Corp?
Genscript Biotech Corp belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Genscript Biotech Corp market cap?
Genscript Biotech Corp's current market cap is $4.9B
Is Genscript Biotech Corp a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Genscript Biotech Corp, including 6 strong buy, 9 buy, 1 hold, 0 sell, and 6 strong sell
